« Return to News | Drug Sponsors

Foundation Medicine, Ariad collaborate on genomic characterization in AP26113 oncology program

Wednesday, November 14, 2012 12:28 PM

Foundation Medicine, a molecular information company, and Ariad Pharmaceuticals, an emerging global oncology company, announced a genomic profiling collaboration to study AP26113, Ariad's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer (NSCLC) and other cancers.

Foundation Medicine will work with Ariad to generate genomic profile information for patients enrolled in Ariad's ongoing phase I/II trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.

"It is important that we have a deep molecular understanding of patients' tumors as they begin treatment with AP26113, especially those patients with complex prior treatment histories," said Timothy P. Clackson, Ph.D., president of R&D and CSO, Ariad. "Foundation Medicine is at the forefront of genomic profiling technologies that will provide molecular insights on a wide array of clinically relevant tumor genes including ALK and EGFR alteration status.”

Michael Pellini, M.D., president and CEO, Foundation Medicine, added, "This study is an example of how cancer complexity often defies single-marker analysis in drug development. We expect that our comprehensive genomic profile will help to identify the optimal patient population for AP26113 and may potentially enable an expedited development timeline."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.